Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Richard A Pittner

Soumitra S Ghosh

Odile Esther Levy

David Geoffrey Parkes

Lawrence J D'Souza

Carolyn M Jodka

Andrew A Young

Mary Erickson

Ved Srivastava

Alain D Baron

Michael R Hanley

Christopher Joseph Soares

Christine Marie Mack

Diana Y Lewis

Samuel Janssen

Kathryn Susan Prickett

John S Ahn

Jonathan David Roth

Sean H Adams

Thao Le

Sarah McQuaid

James R Paterniti, Jr

Lawrence J D'souza

Soumitra G Ghosh

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

GIP analog and hybrid polypeptides with selectable properties

The present invention provides novel Pancreatic Polypeptide Family ('PPF') polypeptides and methods for their use.

Pancreatic polypeptide family motifs, polypeptides and methods comprising the same

GIP and exendin hybrid polypeptides

The present invention relates to novel Pancreatic Polypeptide Family ('PPF') polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.

Pancreatic polypeptide family motifs and polypeptides comprising the same

DPP-IV resistant GIP hybrid polypeptides with selectable properties

Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist.

Methods of treating obesity using PYY[3-36]

The present invention relates to Amylin Family Polypeptide-6 (AFP-6) analogs, which include derivatives and fragments, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the AFP-6 analogs. The AFP-6 analogs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent conditions such as metabolic and cardiovascular disorders, e.g., obesity, diabetes, metabolic syndrome, myocardial ischemia, and increased cardiovascular risk.

Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them

Growing community of inventors

San Diego, CA, United States of America

Richard A Pittner